Compare Cytokinetics Inc (CYTK) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares Silver Trust — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.50B), while iShares Silver Trust trades at $54.49 (market cap $29.58B). The key difference: iShares Silver Trust is far larger — about 3.5× Cytokinetics Inc's market cap, and iShares Silver Trust is more actively traded (20,364,955 versus 2,395,556). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares Silver Trust for 89 Days on average.
| CYTK | SLV | |
|---|---|---|
Market Cap | $8.50B | $29.58B |
Volume | 2,395,556 | 20,364,955 |
Sector | Health | — |
52-Week High | $87.26 | $105.57 |
52-Week Low | $54.76 | $42.40 |
Typical Hold Time | 19 Days | 89 Days |
Enterprise Value | $8.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% amid broader precious metals pressure from rising Treasury yields and Fed rate hike expectations. The ETF shows minimal operational activity with $0 revenue but maintains a strong balance sheet with $13.41 billion in assets against negligible liabilities. Technical indicators signal bearish momentum with moving averages overwhelmingly negative, though RSI levels suggest potential oversold conditions.
While silver faces near-term headwinds from monetary policy, structural demand from industrial applications and inflation hedging provides long-term support. Key risks include Fed policy volatility and dollar strength, but the trust's pure-play silver exposure offers strategic diversification. Current levels may present accumulation opportunities for investors with multi-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
